CAJ | 학술논문

目的：探讨骨痨敌注射液联合常规抗结核药物对初治肺结核临床疗效。方法：将确诊的初治肺结核患者80例随机分为试验组和对照组，试验组强化期采用2HRZE+骨痨敌注射液，对照组采用常规抗结核药物（2HRZE），比较两组患者的痰菌转阴率、临床疗效及不良反应发生率。结果：试验组患者痰菌转阴率及临床疗效明显高于对照组，差异有统计学意义（P<0.05）；两组患者不良反应发生率差异无统计学意义（P>0.05）。结论：骨痨敌注射液联合常规抗结核药物可提高疗效，且无严重不良反应发生，值得临床推广。
목적：탐토골로활주사액연합상규항결핵약물대초치폐결핵림상료효。방법：장학진적초치폐결핵환자80례수궤분위시험조화대조조，시험조강화기채용2HRZE+골로활주사액，대조조채용상규항결핵약물（2HRZE），비교량조환자적담균전음솔、림상료효급불량반응발생솔。결과：시험조환자담균전음솔급림상료효명현고우대조조，차이유통계학의의（P<0.05）；량조환자불량반응발생솔차이무통계학의의（P>0.05）。결론：골로활주사액연합상규항결핵약물가제고료효，차무엄중불량반응발생，치득림상추엄。
Objective:To evaluate the clinical efficacy of GULAODI injector being used to cure Pulmonary tuberculosis.Methods:80 firstly-treaded pulmonary tuberculisis patients are divided into test-group and control-group. Two groups both are treated by the cure of 2HRZE/4HR.Test-group adds GLD totreat to observe the efficacy of the changes of sputumbacteriological conversion、clinical efficacy and the incidence of adverse reactions on the strengthening phase. Results Sputum negative conversion rates and clinical efficacy of test-group is sharply higher than that of control-group(P<0.05).There is no significant difference in incidence of adverse reactions between two groups(P>0.05).Conclusion To cure firstly-treated pulmonary tuberculosis, the GLD injector with chemotherapy can higher the sputum negative conversion and improve the clinical efficacy.It has low side-effect.It is well worthwhile in clinical trertment .